{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-017235","form_type":"8-K","ticker":"GKOS","cik":"0001192448","company_name":"GLAUKOS Corp","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.434534+00:00","generated_at":"2026-06-09T02:03:00.058724+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Glaukos Q3 net sales up 10% to $78M; raises FY2023 guidance to $307-310M","bullets":["Net sales $78.0M (+10% YoY); glaucoma $58.3M (+9%), corneal health $19.7M (+12%).","GAAP net loss $30.4M ($0.63/share); non-GAAP net loss $24.2M ($0.50/share).","Raised FY2023 net sales guidance to $307-310M from $304-308M.","Cash and equivalents $307M at quarter end."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-017235","json":"https://secwatch.observer/filing/0001558370-23-017235.json","markdown":"https://secwatch.observer/filing/0001558370-23-017235.md","text":"https://secwatch.observer/filing/0001558370-23-017235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1192448/000155837023017235/0001558370-23-017235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1192448/000155837023017235/gkos-20231101x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:03:00.058724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b366d42fe8d4e77aa90f12b681a204f0ffa93ce5","claim":"GLAUKOS Corp reported third quarter ended September 30, 2023 results: revenue $78.0 million, net income ($30.4 million, or ($0.63) per diluted share). Guidance raised.","evidence_excerpt":"of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2023. Key highlights include: · Net sales of $78.0 million in Q3 2023 increased 10% year-over-year on a reported basis and 9% year-over-year on a constant currency basis. · Glaucoma net sales of $58.3 million in Q3 2023 increased 9%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1192448/000155837023017235/0001558370-23-017235-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$78.0 million"},{"label":"Net income","value":"($30.4 million, or ($0.63) per diluted share)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}